Liu Xiangxing, Zhang Jiaojiao, Feng Keqing, Wang Simin, Chen Liming, Niu Suping, Lu Qian, Fang Yi
Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Department of Clinical Pharmacy, Ocean University of China, Qingdao, China.
Front Pharmacol. 2022 Nov 14;13:1023533. doi: 10.3389/fphar.2022.1023533. eCollection 2022.
In recent years, several clinical trials have focused on oncolytic virus (OVs) combined with chemotherapy or immune checkpoint inhibitors (ICIs) in solid tumor patients, which showed encouraging effects. However, few studies have concentrated on the summary on the safety and efficacy of the combined treatments. Therefore, we conducted this meta-analysis to explore the safety and curative effect of the combined therapy. We searched the PubMed, Cochrane Library, Embase, and Clinicaltrials.gov databases to comprehensively select articles on OVs combined with chemotherapy or ICIs for the solid tumor treatment. Overall survival (OS), progression-free survival (PFS), 1-year survival rate, 2-year survival rate, objective response rate (ORR), and adverse events (AEs) were the outcomes. Fifteen studies with 903 patients were included in this meta-analysis. The pooled ORR was 32% [95% confidence interval (CI): 27-36%, I = 24.9%, = 0.239]. Median OS and median PFS were 6.79 months (CI: 4.29-9.30, I = 62.9%, = 0.044) and 3.40 months (CI: 2.59-4.22, I = 0.0%, = 0.715), respectively. The 1-year survival rate was 38% (CI: 0.29-0.47, I = 62.9%, = 0.044), and the 2-year survival rate was 24% (CI: 12-37%, I = 0.0%, = 0.805). The most common AEs were fever (63%, CI: 57-69%, I = 2.3%, = 0.402), fatigue (58%, CI: 51-65%, I = 49.2%, = 0.096), chill (52%, CI: 43-60%, I = 0.0%, = 0.958), and neutropenia (53%, CI: 47-60%, I = 0.0%, = 0.944). OVs combined with ICIs showed a better efficacy than OVs combined with chemotherapy, which lends support to further clinical trials of OVs combined with ICIs. In addition, OVs combined with pembrolizumab can exert increased safety and efficacy. The toxicity of grades ≥3 should be carefully monitored and observed. However, high-quality, large-scale clinical trials should be completed to further confirm the efficacy and safety of OVs combined with ICIs. : [https://www.crd.york.ac.uk/PROSPERO/login.php], identifier [RD42022348568].
近年来，多项临床试验聚焦于溶瘤病毒（OVs）联合化疗或免疫检查点抑制剂（ICIs）用于实体瘤患者，显示出令人鼓舞的效果。然而，很少有研究专注于联合治疗安全性和疗效的总结。因此，我们进行了这项荟萃分析以探讨联合治疗的安全性和疗效。我们检索了PubMed、Cochrane图书馆、Embase和Clinicaltrials.gov数据库，以全面筛选关于OVs联合化疗或ICIs用于实体瘤治疗的文章。总生存期（OS）、无进展生存期（PFS）、1年生存率、2年生存率、客观缓解率（ORR）和不良事件（AEs）为观察指标。本荟萃分析纳入了15项研究共903例患者。汇总的ORR为32%[95%置信区间（CI）：27 - 36%，I² = 24.9%，P = 0.239]。中位OS和中位PFS分别为6.79个月（CI：4.29 - 9.30，I² = 62.9% P = 0.044）和3.40个月（CI：2.59 - 4.22，I² = 0.0%，P = 0.715）。1年生存率为38%（CI：0.29 - 0.47，I² = 62.9%，P = 0.044），2年生存率为24%（CI：12 - 37%，I² = 0.0%，P = 0.805）。最常见的AEs为发热（63%，CI：57 - 69%，I² = 2.3%，P = 0.402）、疲劳（58%，CI：51 - 65%，I² = 49.2%，P = 0.096）、寒战（52%，CI：43 - 60%，I² = 0.0%，P = 0.958）和中性粒细胞减少（53%，CI：47 - 60%，I² = 0.0%，P = 0.944）。OVs联合ICIs显示出比OVs联合化疗更好的疗效，这为OVs联合ICIs的进一步临床试验提供了支持。此外，OVs联合帕博利珠单抗可提高安全性和疗效。应仔细监测和观察≥3级毒性。然而，需要完成高质量、大规模的临床试验以进一步证实OVs联合ICIs的疗效和安全性。：[https://www.crd.york.ac.uk/PROSPERO/login.php]，标识符[RD42022348568]
